不同胰岛素类似物对 1 型糖尿病患者氧化应激的影响。 (Ineox 研究) (INEOX)
2021年11月23日 更新者:Virginia Morillas、Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
不同胰岛素类似物对 1 型糖尿病患者氧化应激的影响。低水平干预的临床试验。 (Ineox 研究)
本研究在一组 DM 1 患者中评估了不同电流胰岛素类似物治疗对氧化应激参数的影响
研究概览
详细说明
通过在一组 DM 1 患者中进行的随机研究,评估不同电流类似物治疗对氧化应激参数的影响
胰岛素通过分析:
- - 氧化应激标志物的循环水平:A) 抗氧化:总抗氧化能力 (CAT),B) 氧化:8-iso-prostaglandin F2 alpha (8-iso-PGF2α),酸反应物质硫代巴比妥酸 (TBARS) 和 LDL-氧化。
- - 分析了血糖控制变量(HbA1c 和平均血糖)和变异性(标准差 (SD)、变异系数 (CV) 和 MAGE(血糖波动的平均幅度)和氧化应激参数之间的关系。
目标 2:
研究与过程和氧化状态相关的细胞通路的激活,通过多达 50 个基因的表达阵列,这些基因编码氧化应激反应基因,如 CPT1a(肉碱棕榈酰转移酶 1a,线粒体氧化 b 限制酶),TAS(脂肪酰基合成酶)、乙酰辅酶 A 羧化酶、Acadm(中链酰基脱氢酶)、Acadl(长链酰基脱氢酶)、Acadvl(长链酰基辅酶 A 脱氢酶)、SOD1、Hmox1 和谷氨酰胺-半胱氨酸连接酶 (Gclc)。
研究类型
介入性
注册 (实际的)
300
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Málaga、西班牙
- Regional University Hospital of Malaga
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
16年 至 63年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
纳入标准:
- 年龄在 18 岁至 65 岁(含)之间。
- DM1 在马拉加大学地区医院的糖尿病科进行了两年多的演变,并进行了习惯性随访。
- HbA1c ≤ 10%
- 在研究开始前使用基础 MDI - Bowl 强化治疗超过 12 个月。
- 给予知情同意。
排除标准:
- 慢性肾病、肝病、甲状腺功能障碍(正确治疗控制的甲减除外)。
- 怀孕或怀孕计划。
- 2型糖尿病。
- 高尿酸血症(尿酸≥7 mg / dl 在包含或当前使用别嘌醇治疗时)。
- 缺乏合作(知情同意)。
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
其他:德谷和诺和锐
接受 Tresiba 胰岛素和 NovoRapid 胰岛素治疗的患者
|
16:00 时的基础胰岛素和该基础剂量的优化,早餐前血糖目标为 80-130 mg/dl。
其他名称:
患者已经使用的超速胰岛素和剂量调整以获得餐后血糖水平 < 150 mg/dl
其他名称:
|
其他:Toujeo SoloStar 和 NovoRapid
使用 Toujeo SoloStar 胰岛素和 NovoRapid 胰岛素治疗的患者
|
患者已经使用的超速胰岛素和剂量调整以获得餐后血糖水平 < 150 mg/dl
其他名称:
16:00 时的基础胰岛素和该基础剂量的优化,早餐前血糖目标为 80-130 mg/dl。
其他名称:
|
其他:Tresiba & 优泌乐 Kwikpen
接受 Tresiba 胰岛素和 Humalog kwikpen 胰岛素治疗的患者
|
16:00 时的基础胰岛素和该基础剂量的优化,早餐前血糖目标为 80-130 mg/dl。
其他名称:
患者已经使用的超速胰岛素和剂量调整以获得餐后血糖水平 < 150 mg/dl
其他名称:
|
其他:Toujeo SoloStar 和 Humalog Kwikpen
使用 Toujeo SoloStar 胰岛素和 Humalog kwikpen 胰岛素治疗的患者
|
16:00 时的基础胰岛素和该基础剂量的优化,早餐前血糖目标为 80-130 mg/dl。
其他名称:
患者已经使用的超速胰岛素和剂量调整以获得餐后血糖水平 < 150 mg/dl
其他名称:
|
其他:特雷西巴和阿皮德拉
接受 Tresiba 胰岛素和 Apidra 胰岛素治疗的患者
|
16:00 时的基础胰岛素和该基础剂量的优化,早餐前血糖目标为 80-130 mg/dl。
其他名称:
患者已经使用的超速胰岛素和剂量调整以获得餐后血糖水平 < 150 mg/dl
其他名称:
|
其他:Toujeo SoloStar 和 Apidra
使用 Toujeo SoloStar 胰岛素和 Apidra 胰岛素治疗的患者
|
16:00 时的基础胰岛素和该基础剂量的优化,早餐前血糖目标为 80-130 mg/dl。
其他名称:
患者已经使用的超速胰岛素和剂量调整以获得餐后血糖水平 < 150 mg/dl
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
新的慢速胰岛素类似物的氧化应激标志物
大体时间:6个月
|
评估使用新的慢胰岛素类似物的不同治疗对氧化应激标志物循环水平的影响。
1a) 抗氧化:总抗氧化能力 (CAT),和 1b) 氧化:8-iso-prostaglandin F2 alpha (8-iso-PGF2α)、硫代巴比妥酸反应物质 (TBARS) 和 LDL-氧化
|
6个月
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
糖化血红蛋白
大体时间:6个月
|
血糖控制:糖化血红蛋白
|
6个月
|
平均血糖
大体时间:6个月
|
血糖控制:平均血糖 (mg/dl)
|
6个月
|
标准偏差
大体时间:6个月
|
血糖变异性:标准偏差 [SD]
|
6个月
|
轻度低血糖次数
大体时间:6个月
|
两周内轻度低血糖次数
|
6个月
|
严重低血糖次数
大体时间:6个月
|
最近6个月严重低血糖次数
|
6个月
|
高血糖次数
大体时间:6个月
|
两周内高血糖次数> 250 mg / dl
|
6个月
|
酮症发作
大体时间:6个月
|
最近 6 个月内的酮症发作
|
6个月
|
入院人数
大体时间:6个月
|
最近 6 个月因急性糖尿病失代偿而入院的人数。
|
6个月
|
糖尿病生活质量问卷 (DQOL)
大体时间:6个月
|
关于1型糖尿病患者生活质量的34项
|
6个月
|
1 型糖尿病 (DM1) 患者治疗依从性量表
大体时间:6个月
|
与患者治疗依从性相关的 15 个项目
|
6个月
|
糖尿病痛苦量表。数字数据系统
大体时间:6个月
|
关于 1 型糖尿病患者所遭受的问题和压力的 17 个项目(Polonski y col,2005)
|
6个月
|
对低血糖的恐惧:调查问卷 FH-15
大体时间:6个月
|
15项与1型糖尿病患者对低血糖的恐惧相关
|
6个月
|
糖尿病治疗满意度问卷(DTSQ)。
大体时间:6个月
|
治疗满意度8项
|
6个月
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.
- Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.
- Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S14-20. doi: 10.1016/j.jacc.2008.10.038.
- Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 May;36(5):1384-95. doi: 10.2337/dc12-2480. Epub 2013 Apr 15.
- Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009 Apr;58(4):443-8. doi: 10.1016/j.metabol.2008.10.018. Erratum In: Metabolism. 2009 Jul;58(7):1046. Kitabchi, Abbas Eghbal [corrected to Kitabchi, Abbas E].
- Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001 Jan;86(1):450-3. doi: 10.1210/jcem.86.1.7278.
- Arufe MC, Lu M, Lin RY. Differentiation of murine embryonic stem cells to thyrocytes requires insulin and insulin-like growth factor-1. Biochem Biophys Res Commun. 2009 Apr 3;381(2):264-70. doi: 10.1016/j.bbrc.2009.02.035. Epub 2009 Feb 14.
- Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev. 2009 Jan;89(1):27-71. doi: 10.1152/physrev.00014.2008.
- Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991 Apr;40(4):405-12. doi: 10.2337/diab.40.4.405.
- Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999 Jan;48(1):1-9. doi: 10.2337/diabetes.48.1.1.
- Berg TJ, Nourooz-Zadeh J, Wolff SP, Tritschler HJ, Bangstad HJ, Hanssen KF. Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria. Diabetes Care. 1998 Aug;21(8):1295-300. doi: 10.2337/diacare.21.8.1295.
- Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, Ahmann AJ. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017 Apr;40(4):554-560. doi: 10.2337/dc16-0684. Epub 2017 Jan 23.
- Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN(R) Basal-Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.
- Bravi MC, Armiento A, Laurenti O, Cassone-Faldetta M, De Luca O, Moretti A, De Mattia G. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism. 2006 May;55(5):691-5. doi: 10.1016/j.metabol.2006.01.003.
- Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. doi: 10.2337/diabetes.54.6.1615. No abstract available.
- Ceolotto G, Bevilacqua M, Papparella I, Baritono E, Franco L, Corvaja C, Mazzoni M, Semplicini A, Avogaro A. Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes. 2004 May;53(5):1344-51. doi: 10.2337/diabetes.53.5.1344.
- Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S15-9. doi: 10.1097/01.hjr.0000368193.24732.66.
- Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabet Med. 2010 Aug;27(8):911-7. doi: 10.1111/j.1464-5491.2009.02928.x.
- Ceriello A, Ihnat M. Oxidative stress is, convincingly, the mediator of the dangerous effects of glucose variability. Diabet Med. 2010 Aug;27(8):968. doi: 10.1111/j.1464-5491.2010.02931.x. No abstract available.
- Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2346-50. doi: 10.2337/dc12-2469. Epub 2013 Apr 5.
- Costacou T, Evans RW, Schafer GL, Orchard TJ. Oxidative stress and response in relation to coronary artery disease in type 1 diabetes. Diabetes Care. 2013 Nov;36(11):3503-9. doi: 10.2337/dc12-2378. Epub 2013 Aug 6.
- Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug;19(4):183-93. doi: 10.1016/j.jdiacomp.2005.01.003.
- Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med. 2004 Jul-Dec;10(7-12):65-71. doi: 10.2119/2005-00029.Saltiel.
- Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001 Jul;86(7):3257-65. doi: 10.1210/jcem.86.7.7623.
- Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol. 2007 Jun 4;99(11A):12H-18H. doi: 10.1016/j.amjcard.2007.04.004.
- Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008 Aug;10(4):273-7. doi: 10.1089/dia.2008.0282.
- Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988 Jul-Aug;11(7):567-73. doi: 10.2337/diacare.11.7.567.
- Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care. 1998 Oct;21(10):1736-42. doi: 10.2337/diacare.21.10.1736.
- Fawcett J, Tsui BT, Kruer MC, Duckworth WC. Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Metabolism. 2004 Aug;53(8):1037-44. doi: 10.1016/j.metabol.2004.02.013.
- Francescato MP, Stel G, Geat M, Cauci S. Oxidative stress in patients with type 1 diabetes mellitus: is it affected by a single bout of prolonged exercise? PLoS One. 2014 Jun 6;9(6):e99062. doi: 10.1371/journal.pone.0099062. eCollection 2014.
- Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia. 2008 Feb;51(2):353-60. doi: 10.1007/s00125-007-0870-2. Epub 2007 Nov 27.
- Garcia-Escobar E, Rodriguez-Pacheco F, Haro-Mora JJ, Gomez-Zumaquero JM, Rubio-Martin E, Gutierrez-Repiso C, Soriguer F, Rojo-Martinez G. Effect of insulin analogues on 3t3-l1 adipogenesis and lipolysis. Eur J Clin Invest. 2011 Sep;41(9):979-86. doi: 10.1111/j.1365-2362.2011.02492.x. Epub 2011 Mar 2.
- Goldman J, White JR Jr. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. Ann Pharmacother. 2015 Oct;49(10):1153-61. doi: 10.1177/1060028015597915. Epub 2015 Aug 3.
- Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000 May;23(5):644-9. doi: 10.2337/diacare.23.5.644.
- Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.
- Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015 Dec;38(12):2217-25. doi: 10.2337/dc15-0249. Epub 2015 Jun 17.
- Hoeldtke RD, Bryner KD, Hoeldtke ME, Christie I, Ganser G, Hobbs G, Riggs J. Sympathetic sudomotor disturbance in early type 1 diabetes mellitus is linked to lipid peroxidation. Metabolism. 2006 Nov;55(11):1524-31. doi: 10.1016/j.metabol.2006.06.023.
- Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003 Jul;26(7):2027-31. doi: 10.2337/diacare.26.7.2027.
- Liu HY, Cao SY, Hong T, Han J, Liu Z, Cao W. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem. 2009 Oct 2;284(40):27090-100. doi: 10.1074/jbc.M109.016675. Epub 2009 Aug 4.
- Hojlund K, Poulsen M, Staehr P, Brusgaard K, Beck-Nielsen H. Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes. Eur J Clin Invest. 2002 Dec;32(12):918-23. doi: 10.1046/j.1365-2362.2002.01098.x.
- Jarvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, Lehtimaki T, Ronnemaa T, Viikari J, Raitakari OT. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004 Apr 13;109(14):1750-5. doi: 10.1161/01.CIR.0000124725.46165.2C. Epub 2004 Mar 15.
- Kalra S, Baruah MP, Niazi AK. Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. doi: 10.2174/187221412799015326.
- Korytkowski MT, Salata RJ, Koerbel GL, Selzer F, Karslioglu E, Idriss AM, Lee KK, Moser AJ, Toledo FG. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009 Apr;32(4):594-6. doi: 10.2337/dc08-1436.
- Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000 Jun;49(6):999-1005. doi: 10.2337/diabetes.49.6.999.
- Laaksonen DE, Atalay M, Niskanen L, Uusitupa M, Hanninen O, Sen CK. Increased resting and exercise-induced oxidative stress in young IDDM men. Diabetes Care. 1996 Jun;19(6):569-74. doi: 10.2337/diacare.19.6.569.
- Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142-8. doi: 10.2337/diabetes.49.12.2142.
- Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009 Jan;11(1):45-52. doi: 10.1111/j.1463-1326.2008.00915.x. Epub 2008 Jul 17.
- Makimattila S, Virkamaki A, Malmstrom R, Utriainen T, Yki-Jarvinen H. Insulin resistance in type I diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab. 1996 Feb;81(2):707-12. doi: 10.1210/jcem.81.2.8636292.
- Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009 Jan;11(1):53-9. doi: 10.1111/j.1463-1326.2008.00934.x. Epub 2008 Jul 29.
- Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda G, Santini SA. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care. 2002 Feb;25(2):370-5. doi: 10.2337/diacare.25.2.370.
- Matsuhisa M, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res Clin Pract. 2016 Dec;122:133-140. doi: 10.1016/j.diabres.2016.10.002. Epub 2016 Oct 13.
- Delmastro MM, Piganelli JD. Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol. 2011;2011:593863. doi: 10.1155/2011/593863. Epub 2011 May 18.
- Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010 Mar;53(3):562-71. doi: 10.1007/s00125-009-1574-6. Epub 2009 Nov 5.
- Monnier L, Hanefeld M, Schnell O, Colette C, Owens D. Insulin and atherosclerosis: how are they related? Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15.
- Muchmore DB, Heinemann L, Tamborlane W, Wu XW, Fleming A. Assessing rates of hypoglycemia as an end point in clinical trials. Diabetes Care. 2015 Oct;38(10):e160-1. doi: 10.2337/dc15-0808. Epub 2015 Aug 17. No abstract available.
- Muretta JM, Mastick CC. How insulin regulates glucose transport in adipocytes. Vitam Horm. 2009;80:245-86. doi: 10.1016/S0083-6729(08)00610-9.
- Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol. 2011 Aug 2;108(3 Suppl):42B-51B. doi: 10.1016/j.amjcard.2011.03.015.
- Osterberg O, Erichsen L, Ingwersen SH, Plum A, Poulsen HE, Vicini P. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):221-35. doi: 10.1023/a:1025594110558.
- Scheen AJ. New therapeutic approaches in type 2 diabetes. Acta Clin Belg. 2008 Nov-Dec;63(6):402-7. doi: 10.1179/acb.2008.083.
- Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005 Apr;28(4):950-5. doi: 10.2337/diacare.28.4.950.
- Sanders EJ, Harvey S. Peptide hormones as developmental growth and differentiation factors. Dev Dyn. 2008 Jun;237(6):1537-52. doi: 10.1002/dvdy.21573.
- Singh P, Jain A, Kaur G. Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem. 2004 May;260(1-2):153-9. doi: 10.1023/b:mcbi.0000026067.08356.13.
- Somwar R, Sweeney G, Ramlal T, Klip A. Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther. 1998 Jan-Feb;20(1):125-40. doi: 10.1016/s0149-2918(98)80040-4.
- Steensgaard DB, Schluckebier G, Strauss HM, Norrman M, Thomsen JK, Friderichsen AV, Havelund S, Jonassen I. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013 Jan 15;52(2):295-309. doi: 10.1021/bi3008609. Epub 2013 Jan 3.
- Varvarovska J, Racek J, Stetina R, Sykora J, Pomahacova R, Rusavy Z, Lacigova S, Trefil L, Siala K, Stozicky F. Aspects of oxidative stress in children with type 1 diabetes mellitus. Biomed Pharmacother. 2004 Dec;58(10):539-45. doi: 10.1016/j.biopha.2004.09.011.
- Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.
- Wang J, Alexanian A, Ying R, Kizhakekuttu TJ, Dharmashankar K, Vasquez-Vivar J, Gutterman DD, Widlansky ME. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):712-20. doi: 10.1161/ATVBAHA.111.227389. Epub 2011 Dec 29.
- Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987 Jul 1;245(1):243-50. doi: 10.1042/bj2450243.
- Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):353-63. doi: 10.1002/dmrr.865.
- Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20. doi: 10.1111/j.1463-1326.2005.00567.x.
- Ziegler D, Buchholz S, Sohr C, Nourooz-Zadeh J, Roden M. Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015 Feb;52(1):65-72. doi: 10.1007/s00592-014-0601-3. Epub 2014 Jun 5.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2017年1月20日
初级完成 (实际的)
2020年11月30日
研究完成 (实际的)
2021年11月20日
研究注册日期
首次提交
2017年10月29日
首先提交符合 QC 标准的
2017年10月29日
首次发布 (实际的)
2017年11月1日
研究记录更新
最后更新发布 (实际的)
2021年12月6日
上次提交的符合 QC 标准的更新
2021年11月23日
最后验证
2021年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
1 型糖尿病的临床试验
特雷西巴的临床试验
-
Second Affiliated Hospital, School of Medicine,...招聘中
-
Sansum Diabetes Research InstituteNovo Nordisk A/S完全的